Bon Natural Life Limited announced on May 16, 2025, an exclusive cooperation agreement with Beijing Huahai Keyuan (Tech) Co., Ltd., a prominent functional ingredient distributor in China. This 36-month agreement has a total contract value of US$32 million.
Under the terms of the agreement, Beijing Huahai Keyuan will serve as the exclusive sales partner for BON’s patented postbiotic hypoglycemic ingredients. These ingredients are designed to regulate blood sugar, specifically targeting and cutting post-meal glucose spikes.
The postprandial blood glucose control market is a rapidly expanding sector, with a current market size exceeding $30 billion and sustaining a compound annual growth rate of 7.5%. BON aims to establish a leading position in this market, anticipating meaningful advancements in sales and profits over the next 2-3 years.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.